UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2024

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

0-26642
(Commission
File Number)

87-0494517
(I.R.S. Employer
Identification No.)

322 North 2200 West
Salt Lake City, Utah 84116
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 584-5600

Not applicable
(Full name and address of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Table of each class

Title of each class

Common Stock, $0.01 par value

Trading Symbol(s)

MYGN

Name of each exchange on which registered

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 Results of Operations and Financial Condition.

On January 10, 2024, Myriad Genetics, Inc. (the “Company”) provided a presentation to investors at the 42nd Annual J.P. Morgan Healthcare Conference, which presentation was previously announced by press release and was available via simultaneous webcast. In connection with the presentation and based on the Company’s preliminary results for the quarter and full year ended December 31, 2023, the Company reaffirmed its fiscal year 2023 revenue and non-GAAP guidance previously provided on November 6, 2023 during its third quarter 2023 earnings call. In addition, the Company reaffirmed its guidance that it is on track to achieve positive adjusted operating cash flow in the fourth quarter 2023 and provided guidance on estimated cash, cash equivalents and available credit as of the end of 2023. The full text of the presentation is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The Company also disclosed preliminary financial data for the fourth quarter of 2023, specifically that the Company expects fourth quarter 2023 revenue of between approximately $196 and $197 million, diluted GAAP earnings per share of between ($0.35) and ($0.36), adjusted earnings per share of between $0.02 and $0.03, and GAAP and adjusted gross margin of approximately 70%. The Company further disclosed that it expects revenue growth in fiscal year 2023 of at least 10% year-over-year and prenatal volume growth in the fourth quarter of 2023 of at least 10% year-over-year. Preliminary fourth quarter 2023 non-GAAP results began with the comparable GAAP financial measure and exclude the estimated impact of stock-based compensation expense of approximately $10.3 million, non-cash amortization associated with acquisitions of approximately $10.7 million, costs related to transformation initiatives and other one-time costs of approximately $14.1 million, legal settlement costs of approximately $0.6 million, and tax adjustments of approximately $2.0 million.

The Company is in the process of finalizing its financial results for the quarter and full year ended December 31, 2023, and the foregoing financial guidance, data, and other information is based on available information to date and is derived from preliminary, unaudited internal financial reports. This preliminary, unaudited financial information and data may change in connection with the finalization of the Company’s year-end closing and reporting processes and financial statements for the quarter and full year ended December 31, 2023, and therefore, the foregoing financial guidance, data, and other information may not represent the Company’s actual financial results for the quarter and full year ended December 31, 2023.

FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K and Exhibit 99.1 contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company’s fiscal year 2023 financial guidance, preliminary fourth quarter 2023 financial and operating results, 2024 revenue guidance and long-term financial targets through 2026, the Company’s expectation to achieve positive adjusted operating cash flow in the fourth quarter of 2023, the Company's expectation of 10%+ revenue growth in 2024 through 2026, the Company’s estimated total available cash and credit at year end 2023, roadmaps of expected business highlights in 2024 and 2025, the expected timeline to complete certain enterprise infrastructure and capability investments, and the expected timing of the launch or enhancement of certain new or existing products. These “forward-looking statements” are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: the risk that sales and profit margins of the Company’s existing tests may decline or that the Company may not be able to operate its business on a profitable basis; risks related to the Company’s ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers’ coverage and reimbursement levels for the Company’s tests or the Company’s ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests; the risk that the Company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the Company may not successfully develop new markets or channels for its tests, including the Company’s ability to successfully generate substantial revenue outside the United States; the risk that licenses to the technology underlying the Company’s tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with constructing and operating the Company’s laboratory testing facilities; risks related to public concern over genetic testing in general or the Company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the Company’s ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the Company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses, acquires or develops; the risk that the Company is not able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms, if at all; risks related to the Company’s projections or estimates about the potential market opportunity for the Company’s current and future products; the risk that the Company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the Company’s tests; the risk of patent-infringement claims or challenges to the validity of the Company’s patents; risks related to changes in intellectual property laws covering the Company’s tests, or patents or enforcement, in the United States and foreign countries; risks related to security breaches, loss of data and other disruptions, including from cyberattacks; risks of new, changing and competitive technologies in the United...
States and internationally and that the Company may not be able to keep pace with the rapid technology changes in its industry, or properly leverage new technologies to achieve or sustain competitive advantages in its products; the risk that the Company may be unable to comply with financial operating covenants under the Company’s credit or lending agreements; risks related to the Company’s inability to achieve and maintain effective disclosure controls and procedures and internal control over financial reporting; risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and other factors discussed under the heading “Risk Factors” contained in Item 1A of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 1, 2023 as updated in the Company’s Quarterly Reports on Form 10-Q filed with the SEC on May 4, 2023, August 4, 2023 and November 7, 2023, as well as any further updates to these risk factors filed from time to time in the Company’s Current Reports on Form 8-K. The Company is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

ITEM 9.01 Financial Statements and Exhibits.

<table>
<thead>
<tr>
<th>Exhibit Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Investor Presentation dated January 10, 2024</td>
</tr>
<tr>
<td>104</td>
<td>Cover Page Interactive Data File (embedded within the Inline XBRL document).</td>
</tr>
</tbody>
</table>

The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation.
Revealing the power of genetic science – for everyone

Mission
We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

Vision
As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.
Myriad Genetics at-a-glance

- A leader in genetic testing
  Established franchises in hereditary cancer, pharmacogenomics, and prenatal testing

- 30+ years of scientific and commercial achievements
  1,000+ scientific publications and counting

- 45,000+ active ordering healthcare providers¹
- 69 net promoter score¹
- ~2,700 employees²

- 10%+ annual revenue growth for fourth consecutive quarter³
  Commercial execution driving volume growth; price stability

- Market-leading gross margins; healthy balance sheet

- Innovation in ‘24 and beyond
  Expect to launch multiple differentiated tests in prenatal and oncology through 2026

¹. As of September 2023
². As of June 2023
³. As of third quarter 2023 and excludes contribution from change of revenue estimate

©2023 Myriad Genetics, Inc.
Pillars of long-term growth and profitability

Science and innovation
Top-tier science delivering products that are clinically validated and demonstrate proven utility (quality, access and cost) in real world clinical settings.

Elevated customer experience and commercial execution
Strong digitally enabled commercial platform.

Technology enabled operations
Automated, scalable and cost-effective laboratory operations and technology platform.

Scalable commercial, lab operations and administrative support services
Advanced regulatory, reimbursement, and revenue cycle capabilities.
3 focus areas: Oncology, Women's Health and Pharmacogenomics

**Oncology**
Clarifying cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

- MyRisk®
- ProLaris®
- EndoPredict®
- MyChoice®
- MyRisk® SneakPeek®
- Foresight®

**Women's Health**
A leader in health and wellness with differentiated genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

- MyRisk®
- ProLaris®
- EndoPredict®
- MyChoice®
- MyRisk® SneakPeek®
- Foresight®

**Pharmacogenomics**
Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

- GeneSight®
- Prequel®

**Business**
- Oncologist
- Surgeon
- Genetic Counselor

**Actionable Market Size**
- $23 Billion

**Customer**
- OB/GYN
- Maternal Fetal Medicine
- Primary Care
- Genetic Counselor

**Channel**
- Psychiatrist
- Primary Care
- Nurse Practitioner/Physician Assistant

**$5 Billion Pharmacogenomics Actionable Market Size**

*Customer Source: Data as of 2022 from third-party global consulting firm and internal Company estimates.*
### Diversified portfolio within large, fragmented, actionable markets

<table>
<thead>
<tr>
<th></th>
<th>Oncology</th>
<th>Women's Health</th>
<th>PGx</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFFECTED HCT + GERMLINE</td>
<td>TUMOR PROFILING</td>
<td>HRD</td>
<td>UROLOGY</td>
</tr>
<tr>
<td>Actionable Market Opp. 1</td>
<td>$1.2B</td>
<td>$500M</td>
<td>$20B+</td>
</tr>
<tr>
<td>Market Penetration</td>
<td>-65%</td>
<td>-45%</td>
<td>&lt;5%</td>
</tr>
</tbody>
</table>

#### Myriad Products
- MyRisk
- Precise Tumor
- Precise HRD
- MyChoice CDx
- Prolaris
- Fonsight
- Prequal
- BRACAnalysis CDx
- GeneSight

#### Key Statistics
- **$>30B** of actionable market opportunity
- **<40%** average market penetration across all categories
- **<20%** of market share concentrated among Top 3 participants
- Myriad holds **Top 3 position** in 6 out of 7 active product categories

---

Data as of 2022 from third-party global consulting firm and internal Company estimates.
MyRisk addresses the needs of large and growing markets

<table>
<thead>
<tr>
<th>Unaffected Market – Hereditary Screening</th>
<th>Affected Market – Germline Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actionable market size (US only)</td>
<td>Actionable market size (US only)</td>
</tr>
<tr>
<td>~$3B</td>
<td>~$1.2B</td>
</tr>
<tr>
<td>Market penetration**</td>
<td>Market penetration</td>
</tr>
<tr>
<td>15%</td>
<td>65%</td>
</tr>
<tr>
<td>Market growth**</td>
<td>Market growth**</td>
</tr>
<tr>
<td>High</td>
<td>Mid</td>
</tr>
<tr>
<td>MYGN market share</td>
<td>MYGN market share</td>
</tr>
<tr>
<td>30% - 35%</td>
<td>~20%</td>
</tr>
</tbody>
</table>

**Data as of 2022 from third-party global consulting firm and internal Company estimates

TOTAL U.S. POPULATION

TOTAL U.S. POPULATION WHO WOULD QUALIFY FOR HCT

TOTAL NUMBER OF WOMEN WHO QUALIFY FOR HCT AND ARE ACTIVELY INVOLVED IN THEIR HEALTHCARE

TOTAL NUMBER OF WOMEN WHO ARE NEWLY ELIGIBLE FOR HCT IN THE PAST YEAR

TOTAL NEWLY ELIGIBLE PATIENTS ELIGIBLE TO RECEIVE GERMLINE SCREENING ANNUALLY****

PATIENTS RECEIVING GERMLINE TESTING ANNUALLY

*Data as of 2022 from third-party global consulting firm and internal Company estimates
**High single digits
**Mid single digits
****In domain of focus
Significant opportunity to accelerate MyRisk growth across Women’s Health, Imaging, Oncology and Urology

Roadmap of expected highlights

2024
- MyRisk patient portal
- MyRisk Medical Management Tool Enhancements
- RiskScore studies
- Breast Cancer Risk Assessment Program

2025
- Panel Expansion | WES (whole exome sequencing)
- BRAC CDx to NGS

Hereditary cancer test volume

Q3'22 Q4'22 Q1'23 Q2'23 Q3'23

Volume Growth (YOY) +4% +16% +24% +20% +18%

+19% Q3'23 YOY Volume Growth (YOY)
GeneSight is the market-leading PGx test helping address the Nation’s mental health crisis

GeneSight designed to help physicians understand how patients will respond to medications used to treat depression, anxiety, ADHD, and other psychiatric conditions.

2 Million +
people have taken the GeneSight test.

7 Clinical Studies
published in peer reviewed journals, including independent randomized controlled trial in JAMA.

Ordered by tens of thousands of clinicians to inform medication selection and dosing.
Measures multiple genomic variants for each individual to categorize medications and provide clinical considerations.
Market-leading psychiatric PGx test and the only test backed by seven clinical studies published in peer-reviewed journals.

Designed to help physicians and patients avoid multiple medication trials by informing which medications may require dose adjustments, be less likely to work, or have increased risk of side effects.
Strong commercial execution driving significant volume growth in the last twelve months

Roadmap of expected highlights

2024
- Health Economic Outcome Research (HEOR) study
  - Significant opportunity to improve payor coverage and ASP

2025
- Postpartum Clin Dev Protocol & Study

Figures in thousands

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 '23 LTM Volume Growth (YoY)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q3 '22</td>
</tr>
<tr>
<td>YoY Growth</td>
<td>+24%</td>
</tr>
</tbody>
</table>

*Data as of 2023 from third-party global consulting firm and internal Company estimates
**Projected
***This study used data from the Optum Labs Data Warehouse, composed of de-identified administrative claims data for both commercially insured and Medicare Advantage enrollees. The claims data were linked on a de-identified basis with PGx test results.
Prolaris designed to help determine optimal treatment planning for patients with localized prostate cancer

Prolaris utilizes two validated thresholds to identify men that are:
- Safe for active surveillance (low-risk patients)
- Candidates for a singular type of therapy (medium-risk patients)
- Candidates for multiple types of therapy at once (high-risk patients)

Lower Prolaris Score

- Active surveillance (low-risk patients)
- Single-modal treatment (medium-risk patients)
- Multi-modal treatment (high-risk patients)

Higher Prolaris Score

RESEARCH VALIDATION
Prolaris identified >86% of low-risk patients as candidates for active surveillance*

Strong runway for Prolaris with an opportunity to capture more market share with compelling updates

Roadmap of expected highlights

2024
- Expanded coverage from UnitedHealthcare
- ARR (Absolute Risk Reduction) report
- Publish 3-yr Metastasis study

2025
- Prolaris Post-RP launch

*Data as of 2022 from third-party global consulting firms and internal Company estimates
**Current
Comprehensive prenatal care with differentiated products and reliable technology

**Prequel® Prenatal Screen**

Shown to deliver accurate answers to patients regardless of age, ancestry, or body mass index—the Prequel Prenatal Screen with AMPLIFY™ helps determine a pregnancy’s risk for a variety of chromosomal conditions.

- **AMPLIFY fetal fraction amplification** delivers first-time accurate results to >99.9% of patients at 10 weeks.**
- Industry-low screening failure rate*** reduces the chance of repeat screens or unnecessary, invasive diagnostics such as amniocentesis.


**Foresight® Carrier Screen**

Foresight identifies couples at risk of passing down serious, inherited conditions to their children to guide informed planning, preparation, and care.

- Highest published at-risk couple detection rate for serious conditions (1 in 22 couples)**
- >99% detection rate for the vast majority of genes in couples across all ancestries***

Myriad genetics®
A market that continues to grow with potential tailwinds from guideline expansion

<table>
<thead>
<tr>
<th>Actionable market size (US only)*</th>
<th>Market penetration*</th>
<th>Market growth**</th>
<th>MYGN market share*</th>
<th>Low single digits</th>
<th>Low single digits</th>
<th>Low-to-mid teens</th>
</tr>
</thead>
<tbody>
<tr>
<td>~$1.3B</td>
<td>45-55%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>~$950M</td>
<td>40-50%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Data as of 2022 from third-party global consulting firm and internal Company estimates
**Expected

Roadmap of expected highlights

2024
- Foresight on NovaSeq
- FirstGene Launch
- Various Prequel studies
- Foresight Universal Plus
<table>
<thead>
<tr>
<th>Team Engagement</th>
<th>Market Perception and Customer Service Levels</th>
<th>Efficiency &amp; Speed</th>
<th>Revenue Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>86%</td>
<td>69% Net Promoter Score among current Myriad providers ordering across our testing portfolio</td>
<td>5.7 days Rapid turn-around times critical for patients making time-sensitive care decisions</td>
<td>+$58M Increase in collections from 2021 to 2023 with fully automated revenue cycle platform</td>
</tr>
<tr>
<td>Of our team rate Myriad as a “Great Place To Work”</td>
<td>+1300 bps Favorable consideration among providers aware of our efforts to share data with ClinVar*</td>
<td>8% YOY reduction in COGS per test scaling with growth, quality and regulatory requirements**</td>
<td>54 Days Industry leading Days Sales Outstanding (DSO) improved 7 days from Q3 22</td>
</tr>
<tr>
<td>9% Employee turnover, approximately half of what it was in 2021</td>
<td>81% YOY sales productivity increase with structural optimization, automation and accelerating marketing demand</td>
<td>+20% +20% YOY sales productivity increase with structural optimization, automation and accelerating marketing demand</td>
<td>+$40M Estimated revenue opportunity through 2026 from improving revenue cycle operations</td>
</tr>
</tbody>
</table>

* SOURCE: 2022 survey conducted by Edelman HCP ETM Pulse 2022. ** Excluding contribution from SneakPeak Early Gender DNA test.

All data as of September 30, 2023 except as otherwise noted.

December 2022 Base: HCPs who were not aware of the Clinvar Announcement (n=65) / HCPs who were aware of the Clinvar Announcement (n=114)

* Excluding and Related to Clinvar Early Gender DNA test.

* Excluding and Related to Clinvar Early Gender DNA test.
## Enterprise infrastructure and capability investments

<table>
<thead>
<tr>
<th></th>
<th>2022 Q1</th>
<th>2022 Q2</th>
<th>2022 Q3</th>
<th>2022 Q4</th>
<th>2023 Q1</th>
<th>2023 Q2</th>
<th>2023 Q3</th>
<th>2023 Q4</th>
<th>2024 Q1</th>
<th>2024 Q2</th>
<th>2024 Q3</th>
<th>2024 Q4</th>
<th>2025 Q1</th>
<th>2025 Q2</th>
<th>2025 Q3</th>
<th>2025 Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td>NovaSeq Transitions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whole Exome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Facility</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Construction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMR Integrations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### $80M* investment in modern labs

### $12M annual savings starting in 2025

- NovaSeq Transitions: Previous protocols shift to automated sequencing
- Whole Exome: Expanding exome capability to undermined MyRisk, Foresight, Precise, and other products
- South San Francisco innovation campus construction
- Salt Lake City production site campus construction
- Transition Innovation operations to new Salt Lake City campus
- Transition Production to Salt Lake City
- Transition Salt Lake City research lab products to new campus
- Design and build first phases of automation
- Early phase Prenatal lab automation
- Field automates Prenatal labs
- Accelerating pace of EMR integrations through EMR providers (e.g., Epic and Flatiron) - ~1,200 new integrations in 2023, ~1,850 in 2024

---

* >85% of investment is estimated to be capitalizable expense
Product roadmap summary

- **MyRisk**
  - Q1: Tele-Counseling
  - Q3: MyRisk patient portal
  - Q4: MyRisk panel expansion

- **Prolaris**
  - Q2: Pathology R&D alignment
  - Q2: Prostate Panel

- **Foresight Universal**
  - Q1: Pre-launch Study
  - Q2: Study
  - Q3: Full Launch

- **FirstGene**
  - Q1: Validation
  - Q3: Study
  - Q4: Full launch

- **MyChoice CDx**
  - Q4: Induction Expression in g. Breast and Prostate

- **Precise Liquid**
  - Q4: Launch

- **Precise MRI**
  - Q4: (Research Only)
  - Q4: Pharma Availability
  - Q2: Commercial Launch
## Active pipeline to better serve patients and providers

### Women’s Health

<table>
<thead>
<tr>
<th><strong>FirstGene™</strong></th>
<th><strong>Foresight™ Universal Plus</strong></th>
<th><strong>Precise™ Tumor</strong></th>
<th><strong>Precise™ Liquid</strong></th>
<th><strong>Precise™ MRD</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple prenatal screen</td>
<td>Expanded carrier screen</td>
<td>Robust tumor profiling &amp; therapy selection</td>
<td>Robust tumor profiling &amp; therapy selection</td>
<td>Minimal residual disease monitoring</td>
</tr>
</tbody>
</table>

### Key advantages
- Faster turnaround time
- 3x lower cost of goods
- Established reimbursement

### Oncology

<table>
<thead>
<tr>
<th><strong>What is It?</strong></th>
<th><strong>What is It?</strong></th>
<th><strong>What is It?</strong></th>
<th><strong>What is It?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrated assay for NIPS + carrier screen + fetal recessive status + feto-maternal blood compatibility on a single blood draw on one person</td>
<td>Pioneering expanded carrier screen that uses NGS to find pathogenic variants underlying recessive disease. 274 gene expansion in ACOG guidelines (anticipated.)</td>
<td>Pan-cancer comprehensive genomic profiling test using Illumina TruSight Oncology 500; may serve as first-line offering</td>
<td>Monitoring test based on whole genome sequencing to deeply interrogate tumor, detect recurrence earlier and help guide treatment decisions</td>
</tr>
</tbody>
</table>

### Key Advantages
- Panel size ~2x size (500 genes) of lead competitor; uses both DNA/RNA; ease of use as part of Precise Oncology Solutions
- Established reimbursement path

---

Myriad genetics
FirstGene: Transformative prenatal screen running multiple tests at once

Current PROBLEMS with prenatal genetic screening

- Providers don’t have enough time to talk about genetics
- Only 50% utilization of carrier screening
- Only 30% of fathers get screened when mother is a carrier
- Low gross margins on NIPS and ECS

New SOLUTION

- Easier for providers to administer integrated offering
- No need to screen the father
- Estimated 30-40% higher gross margins compared to Foresight or Prequel alone
Oncology: Expanding breadth of portfolio addressing real-world community needs

Planed Product Expansion

MyRisk
MyRisk RiskScore
Polaris
EndoPredict
MyChoice CDx
Precise Tumor
Precise Liquid
Precise MRD
BRACAnalysis CDx

High Risk Screening > Surgical Decisions > Prognostic Testing > Treatment Selection & Clinical Trials > Measurable Residual Disease > Monitoring Recurrence

2024E Launch expected
2025E Launch expected
High-definition MRD: Differentiation built upon existing competencies

- Tumor + normal sample prep and sequencing
- Bioinformatic identification of somatic variants
- cfDNA isolation and targeted sequencing
- Detect presence or absence of tumor cfDNA

Comparable Myriad test: MyChoice® CDx

- Myriad MRD Companion Diagnostic Test
- Existing and proprietary* chemistry and technology

More Targeted tumor sites increases sensitivity

<table>
<thead>
<tr>
<th>Competitor</th>
<th>16 sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVI</td>
<td>1000 sites</td>
</tr>
</tbody>
</table>

Monitoring Test Economics - Gross Margin (Est.) per Patient

- 1st sample (Tumor + Blood)
- 2nd (Blood)
- 3rd (Blood)
- 4th+ sample (Blood)

*patents pending

Myriad genetics®
Precise MRD: Partnerships with world-leading collaborators

“

We anticipate the MRD test from Myriad will be more sensitive and specific than many other ctDNA offerings for monitoring the response and, therefore, may more accurately identify the patients who will or will not benefit from certain therapies. Importantly, some of these patients may go undetected on a less-sensitive MRD test.”

Dr. Pedram Razavi
Director of Liquid Biopsy & Genomics
Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering

Breast cancer: Two-phase study of 100 patients with metastatic breast cancer in neoadjuvant and adjuvant setting.

MD Anderson Cancer Center

Renal cancer: Testing 120 patients with recurrent RCC to assess clinical validity on Radiation + MRD
2023 revenue, adjusted gross margin, adjusted opex and adjusted EPS by quarter

<table>
<thead>
<tr>
<th>Total revenue</th>
<th>Adjusted Gross Margin*</th>
<th>Adjusted Operating Expense*</th>
<th>Adjusted EPS*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1 '23</td>
<td>Q2 '23</td>
<td>Q3 '23</td>
</tr>
<tr>
<td>$155</td>
<td>181.2</td>
<td>183.5</td>
<td>191.9</td>
</tr>
<tr>
<td>+11%</td>
<td>YOY YTD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Q1 '23</td>
<td>Q2 '23</td>
<td>Q3 '23</td>
</tr>
</tbody>
</table>

2023 guidance: $747 - $753

69% - 70%

$548 - $553

$(0.33) - $(0.28)

*Final year 2023 non-GAAP guidance begins with the comparable GAAP financial measures and excludes the estimated impact of stock-based compensation expense of approximately $40 million, non-cash amortization associated with acquisitions of approximately $48 million and special items such as restructuring and transformation initiatives of approximately $51 million, legal settlement costs of approximately $14 million, and tax adjustments of approximately $8 million.

Q4 '23 figures reflect the amount to achieve the mid-point of the 2023 guidance range.

Myriad Genetics
# Reaffirm 2023 revenue and non-GAAP financial guidance and long-term financial targets

All figures in millions, except per share amounts

<table>
<thead>
<tr>
<th>Financial Measure</th>
<th>2023 Guidance</th>
<th>2023 Comments</th>
<th>2024-2026 Commentary</th>
<th>Additional Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$747 - $753</td>
<td>2023 annual growth between 10% - 11% over 2022.</td>
<td>Target total revenue of over $1 billion in 2026. This revenue target includes modest contribution from planned new products and no contribution from future M&amp;A.</td>
<td></td>
</tr>
<tr>
<td><strong>Gross Margin %</strong></td>
<td>69% - 70%</td>
<td>GM expected to fluctuate in any quarter given seasonality.</td>
<td>GM expected to fluctuate in any quarter given product mix, pricing trends and seasonality.</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted operating expenses</strong></td>
<td>$548 - $553</td>
<td></td>
<td>Balance ongoing investment in R&amp;D with ongoing cost controls in SG&amp;A.</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EPS</strong></td>
<td>$(0.33) - $(0.28)</td>
<td>Adjusted EPS is expected to reach positive adjusted profitability and adjusted operating cash flow in Q4 '23.</td>
<td>Target adjusted operating income of approximately $100 million in 2026**, or 10% of total revenue in 2026. Adjusted operating cash flow is expected to be in-line with adjusted operating income trend.</td>
<td></td>
</tr>
</tbody>
</table>

** Assumes currency rates as of November 6, 2023.

** Fiscal year 2023 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46 million, non-cash amortization associated with acquisitions of approximately $43 million, special items such as costs related to transformation initiatives of approximately $24 million, legal settlement costs of approximately $114 million, and tax adjustments of approximately $8 million.

** 2026 adjusted operating income target begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $46 million, non-cash amortization associated with acquisitions of approximately $43 million, special items such as costs related to transformation initiatives of approximately $4 million, and tax adjustments of approximately $0 million.
Increased financial flexibility; On-track to achieve positive adjusted operating cash flow in Q4 ‘23

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cash and cash equivalents at end of third quarter of 2023*</td>
<td>$86.3</td>
</tr>
<tr>
<td>Amount available to draw under the asset-based credit facility**</td>
<td>28.2</td>
</tr>
<tr>
<td>Net proceeds from follow-on equity offering</td>
<td>117.6</td>
</tr>
<tr>
<td>Cash payment of securities class action settlement and first Ravgen installment in Q4 2023</td>
<td>(62.5)</td>
</tr>
<tr>
<td>Estimated capital expenditures, capitalization of internal-use software costs and cash flow from operations in Q4 ‘23</td>
<td>(7.0)</td>
</tr>
<tr>
<td>Estimated total available cash and cash equivalents and availability under credit facility at year end 2023</td>
<td>$162.6</td>
</tr>
</tbody>
</table>

* Cash and cash equivalents at the end of the Q3 ‘23 reflects the initial cash payment of $20 million for the securities class action settlement.

** The amount available to draw under the ABL facility is based on a maximum ABL facility of $115 million. In October 2023, Myriad increased the size of the ABL facility to $115 million to $160 million.

Raised net $118 million in upsized and oversubscribed equity offering

Increased size of asset-based credit facility to $115 million from $90 million.
<table>
<thead>
<tr>
<th>Revenue growth expected to accelerate 10%+ in ‘24–’26</th>
<th>Provided 2024 full-year revenue guidance of $815 - $835 million reflecting annual growth of 9-11% over midpoint of 2023 revenue guidance range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right to win with core products driving market share gains</td>
<td>Enhanced commercial execution generating double-digit volume growth as adoption rates and competitive position improves</td>
</tr>
<tr>
<td>Pipeline addresses large growth markets</td>
<td>Robust and differentiated product pipeline opens access to incremental multi-billion-dollar markets</td>
</tr>
<tr>
<td>Operating leverage, profitability, and positive cash flow</td>
<td>Strength of business model, technology platform and enhanced laboratory capabilities to drive operating leverage, profitability and cash flow in 2024–2026</td>
</tr>
<tr>
<td>Capital deployment</td>
<td>Disciplined capital deployment; continue to invest in high ROI opportunities within core channels</td>
</tr>
</tbody>
</table>

Myriad Genetics
Q&A
Appendix
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th>Nine months ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 30</td>
<td>September 30</td>
</tr>
<tr>
<td>Adjusted Gross Margin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Gross Profit</td>
<td>$134.3</td>
<td>$136.6</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>0.4</td>
<td>1.0</td>
</tr>
<tr>
<td>Costs compensation</td>
<td>0.4</td>
<td>1.1</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Adjusted Gross Profit</td>
<td>$139.1</td>
<td>$139.4</td>
</tr>
<tr>
<td>Adjusted Gross Margin</td>
<td>77.4%</td>
<td>78.9%</td>
</tr>
</tbody>
</table>

(1) Includes all items less cost of testing from the Government Consolidated Statements of Operations.

<table>
<thead>
<tr>
<th></th>
<th>Three months ended</th>
<th>Nine months ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 30</td>
<td>September 30</td>
</tr>
<tr>
<td>Adjusted Operating Expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Operating Expenses</td>
<td>$146.4</td>
<td>$151.0</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>(10.1)</td>
<td>(10.1)</td>
</tr>
<tr>
<td>Goodwill and intangible asset impairment charges</td>
<td>(28.7)</td>
<td>(28.7)</td>
</tr>
<tr>
<td>Costs compensation</td>
<td>(11.9)</td>
<td>(11.9)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>2.9</td>
<td>2.9</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>46.5</td>
<td>153.3</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>0.3</td>
<td>0.8</td>
</tr>
<tr>
<td>Adjusted Operating Expenses</td>
<td>$137.3</td>
<td>$127.0</td>
</tr>
</tbody>
</table>

(1) Includes all items less research and development expense, selling, general, and administrative expense, and goodwill and intangible asset impairment charges from the Government Consolidated Statements of Operations.

©2024 Myriad Genetics, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

(Information data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended September 30,</th>
<th>Nine months ended September 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td>Adjusted Operating Income (Loss)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAAP Operating Loss</td>
<td>$(60.1)</td>
<td>$(65.0)</td>
</tr>
<tr>
<td>Acquisition - amortization of intangible assets</td>
<td>10.7</td>
<td>10.1</td>
</tr>
<tr>
<td>Goodwill and long-lived asset impairment charges</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Equity compensation</td>
<td>13.7</td>
<td>8.4</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>2.8</td>
<td>4.7</td>
</tr>
<tr>
<td>Legal charges, net of insurance remittance</td>
<td>15.1</td>
<td>-</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>2.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Adjusted Operating Loss</td>
<td>$(2.3)</td>
<td>$(20.0)</td>
</tr>
</tbody>
</table>

|                      | Three months ended September 30, | Nine months ended September 30, |
|                      | 2023     | 2022     | 2023     | 2022     |
| Adjusted Net Income (Loss) |                     |                                    |
| GAAP Net Loss         | $(63.3)  | $(65.1)  | $(222.1) | $(96.7)  |
| Acquisition - amortization of intangible assets | 10.7      | 10.1      | 20.0      | 20.4      |
| Goodwill and long-lived asset impairment charges | -        | -        | -10.7     | -10.7     |
| Equity compensation   | 13.7     | 8.4      | 30.9      | 29.9      |
| Transformation initiatives | 2.8      | 4.7      | 20.8      | 12.8      |
| Legal charges, net of insurance remittance | 15.1      | -        | 153.3     | (32.9)    |
| Other adjustments     | 2.4      | 0.3      | (0.5)     | (0.7)     |
| Tax adjustments       | 0.4      | 4.5      | 6.0       | (14.3)    |
| Adjusted Net Loss     | $(5.0)   | $(16.2)  | $(20.2)   | $(34.3)   |

Weighted average shares outstanding:

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td>81.9</td>
<td>80.7</td>
</tr>
<tr>
<td>Diluted</td>
<td>81.9</td>
<td>80.7</td>
</tr>
</tbody>
</table>

Adjusted Earnings Per Share:

<table>
<thead>
<tr>
<th></th>
<th>2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic</td>
<td>$(0.05)</td>
<td>$(0.14)</td>
</tr>
<tr>
<td>Diluted</td>
<td>$(0.05)</td>
<td>$(0.14)</td>
</tr>
</tbody>
</table>

(1) To calculate Adjusted Earnings Per Share, or adjusted EPS,
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022
(unaudited data in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Three months ended September 30, 2023</th>
<th>2022</th>
<th>Nine months ended September 30, 2023</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flow from operations</td>
<td>$ (28.6)</td>
<td>$(1.8)</td>
<td>$ (56.2)</td>
<td>$(9.0)</td>
</tr>
<tr>
<td>Transformation initiatives</td>
<td>2.8</td>
<td>4.7</td>
<td>15.1</td>
<td>12.4</td>
</tr>
<tr>
<td>Legal charges, net of insurance reimbursement</td>
<td>21.1</td>
<td>–</td>
<td>23.3</td>
<td>49.9</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>–</td>
<td>–</td>
<td>0.4</td>
<td>–</td>
</tr>
<tr>
<td>Adjusted operating cash flow</td>
<td>$(2.7)</td>
<td>$ 2.9</td>
<td>$(17.4)</td>
<td>$(8.7)</td>
</tr>
<tr>
<td>Capital expenditures</td>
<td>(10.9)</td>
<td>(17.7)</td>
<td>(53.2)</td>
<td>(30.7)</td>
</tr>
<tr>
<td>Capitalization of internal-use software costs</td>
<td>(2.1)</td>
<td>–</td>
<td>(6.6)</td>
<td>–</td>
</tr>
<tr>
<td>Adjusted free cash flow</td>
<td>$(15.7)</td>
<td>$(14.6)</td>
<td>$(77.2)</td>
<td>$(87.4)</td>
</tr>
</tbody>
</table>
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months ended September 30, 2023 and 2022

(unaudited data in millions, except per share amounts)

Following is a description of the adjustments made to GAAP financial measures:

- **Acquisition – amortization of intangible assets** – represents recurring amortization charges resulting from the acquisition of intangible assets.
- **Depreciation and amortization asset impairment charges** – impairment charges on goodwill and licenses.
- **Equity compensation** – non-cash equity-based compensation provided to Myriad Genetics employees and directors.
- **Transformation initiatives** – transition costs such as consulting and professional fees related to transformation initiatives, and other costs resulting from the company’s decision to close the use of its former corporate headquarters in Salt Lake City, Utah. With respect to the adjusted free cash flow reconciliation, the cash flow effect of transformation initiatives excludes non-cash items such as accelerated depreciation.
- **Legal charges, net of insurance reimbursement** – one-time legal expenses related to the settlement of the 2002 litigation, of which $0.7 million of payment is contingent upon certain future events. For the nine months ended September 30, 2023, legal charges, net of insurance reimbursement primarily includes the amounts related to the settlement of the 2002 litigation and a $7.9 million settlement of the securities class action lawsuit. For the nine months ended September 30, 2022, legal charges, net of insurance reimbursement includes the gain from reimbursement of prior legal expenses and settlements. With respect to the adjusted free cash flow reconciliation, the cash flow effect includes each paid for settlements in the related period.
- **Other adjustments** – other one-time non-recurring expenses including consulting and professional fees related to prior year acquisitions, charges in the fair-value of contingent consideration related to acquisitions and reclassifications of cumulative translation adjustments to income upon liquidation of an investment in a foreign entity.
- **Tax adjustments** – tax expense/(benefit) due to non-GAAP adjustments, differences between book and tax reporting for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United States. A valuation allowance of $37.3 million was not recognized for non-GAAP purposes given the company’s historical and forecasted positive earnings performance.